Latest releases

11.01.2021

PR

Herantis Pharma Plc’s to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
18.12.2020

FN, IT, PR

Herantis Pharma Oyj : Managers’ Transactions – Tone Kvåle
17.12.2020

FN, PR

Herantis Pharma and Nanoform Sign a Letter of Intent (LOI) for Collaboration
02.12.2020

FN, GR, PR

Decisions of Herantis Pharma Plc’s Extraordinary General Meeting of shareholders
17.11.2020

LR, PR

Herantis Pharma Announces Favorable 24-Month Follow-Up Review from Phase I Lymfactin® []Trial in Breast Cancer Associated Lymphedema
15.09.2020

N, PR

Herantis Pharma publishes a July-September newsletter
11.09.2020

PR

Registration Information for Herantis Pharma’s Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout
04.09.2020

GR, PR

Herantis Pharma Plc Announces Appointment of Investor Relations Team
04.09.2020

CR, PR

Herantis Pharma to Host a Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout
27.08.2020

CR, PR

Herantis Pharma Plc Announces CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months

Quick links

Analyst Coverage »

Financial Calendar »

General Meetings »

Financial Information »

Share Information »

Share Monitor »

Investor Relations »

Corporate Governance »